Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.
Augeul-Meunier K et al. Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0122-8. [Epub ahead of print].

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
Striha A et al. Trials. 2018 Mar 7;19(1):169. doi: 10.1186/s13063-018-2524-8.

Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy.
Toocheck C et al. BMJ Case Rep. 2018 Mar 9;2018. pii: bcr-2017-223611. doi: 10.1136/bcr-2017-223611.

Elotuzumab and Dexamethasone for Relapsed or Refractory Multiple Myeloma Patients: A Retrospective Study.
Gross Z et al. Eur J Haematol. 2018 Mar 10. doi: 10.1111/ejh.13058. [Epub ahead of print].

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1.
Garderet L et al. Leukemia. 2018 Mar 12. doi: 10.1038/s41375-018-0091-3. [Epub ahead of print].

Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X et al. Pharmacoeconomics. 2018 Mar 26. doi: 10.1007/s40273-018-0644-3. [Epub ahead of print].

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Knauf W et al. Leuk Res. 2018 Mar 14;68:90-97. doi: 10.1016/j.leukres.2018.03.008. [Epub ahead of print].